Stem cell research is one of the hot spots in the field of biomedicine and has broad application prospects. Stem cells have the ability of self-renewal and multi-directional differentiation, and can differentiate into a variety of cell types. Therefore, they have great potential in tissue and organ repair and regeneration, and in solving major refractory diseases. In recent years, with the continuous development of stem cell research, we have seen many breakthrough achievements applied in clinical practice, bringing new hope for the treatment of many diseases. In China, stem cell research has also received extensive attention and support. The Chinese government has increased its investment in stem cell research, strengthened the construction of talent team for stem cell research, and promoted the development of stem cell research in China. At the same time, Chinese scientists also actively participate in international cooperation to jointly promote the development of stem cell research. China has entered the forefront of the world in this field and has made a series of important research achievements. In order to promote the research, application and industrialization of gene and cell technology and products in medicine, and promote the high-quality development of medical and health care and mass health industry, the country, provinces and cities will also introduce relevant policies to support them in 2023.

In the field of stem cells, many enterprises have also been actively involved and made certain achievements. Yuan Yafei, a former member of the National Committee of the Chinese People's Political Consultative Conference (CPPCC) and chairman of the Triple Cell Group, suggested that relevant departments should further improve relevant policies and accelerate the use of umbilical cord blood for clinical treatment of non blood system diseases. We will give full play to the resource value of the seven umbilical cord blood banks in China and make the application of umbilical cord blood in China take the lead in the world. In addition, after the extraction of hematopoietic stem cells from cord blood, the plasma still contains a large number of usable components. Now China's fetal bovine serum and platelet rich plasma basically rely on imports. Yuan Yafei suggested further improving relevant policy documents, hoping to effectively utilize the non cellular components of umbilical cord blood and "turn waste into treasure".

Yuan Yafei, a former CPPCC member and well-known entrepreneur

It is reported that, in recent years, Yuan Yafei's Sanyi Group has actively laid out the storage business of umbilical cord blood hematopoietic stem cells. In 2016, Sanyi Group and Nanjing Xinbai participated in the acquisition fund to acquire the International Cord Blood Bank Group (CO Group) listed on the New York Stock Exchange. Nanjing Xinbai acquired 20% equity of Singapore listed Cordlife Group and 76% equity of Shandong Qilu Stem Cell Engineering Co., Ltd. CO Group and Qilu Stem Cell Company have four of the seven umbilical cord blood bank licenses issued by the National Health and Family Planning Commission, and enjoy exclusive business rights in Beijing, Guangdong, Zhejiang and Shandong. The total related reserves of umbilical cord blood of Sanyi Group exceed 1.6 million, and it is the world's largest storage enterprise of umbilical cord blood hematopoietic stem cells. In February 2017, Sanyi Group also participated in the establishment of a medical M&A fund to acquire the high-tech biological enterprise Fandi Gene, officially entering the field of gene testing. The Group is now the leading enterprise in the domestic stem cell industry.